Posible retraso de entre 1 semana u 1 mes en el tema ... todo bajo control .
By Natalie Harrison
Wed Dec 1, 2010 10:07am EST
LONDON, Dec 1 (IFR) - Spanish pharmaceutical group Grifols' (GRLS.MC) planned USD1.1bn high-yield bond, which will complete its acquisition financing for U.S. rival Talecris Biotherapeutics, may be pushed back to January, a banker familiar with the deal said.
The company, rated B1/BB-, signed a credit agreement for its USD3.4bn senior secured debt facilities last week, consisting of a USD1.5bn Term Loan A, USD1.6bn Term Loan B and a USD300m revolver.
"The last piece of the puzzle is the high-yield bond, which may happen in the next week or so, or may slip to January," said the banker, noting the volatility in credit markets caused by the euro zone sovereign debt crisis.
Although the group has a Spanish parent, over 75% of its revenues are from outside of Spain, the banker said, which means it should not be affected by concerns about peripheral European countries.
Deutsche Bank, Nomura, BBVA, BNP Paribas, HSBC and Morgan Stanley are the leads on the deal.